Ala (Thioctic Acid)

Quick links

Choose a section

Quick links to important sections

Advertisements

Ala (Thioctic Acid)

Advertisements
Advertisements

Overview of Ala (Thioctic Acid)

Property Description
Active ingredient Thioctic Acid (Alpha-lipoic acid, ALA)
Pharmacological class Metabolic agent, Antioxidant
Dosage Forms Oral solid forms, Parenteral solutions
Origin Endogenous substance (naturally produced in the body)
Solubility Type Amphipathic (fat and water soluble)

What is Thioctic Acid (ALA) and What Type of Medicine is It?

The medicine Ala is a formulation containing the active ingredient Thioctic Acid, also known scientifically as Alpha-lipoic acid (ALA). This substance is principally classified as an endogenous metabolic agent and a broad-spectrum antioxidant. Thioctic Acid is recognized as an endogenous substance because it is naturally synthesized within the human body, serving as a vital coenzyme in the mitochondrial process of energy generation. For pharmaceutical use, however, it is produced as a synthetic single-ingredient product, belonging to the larger pharmacological grouping of vitamin and mineral-like preparations. Thioctic Acid is indicated primarily for its antioxidant and metabolic support properties. This indicates the medicine is generally approved for its role in cellular protection and energy management.


Composition and Available Forms of Alpha-Lipoic Acid

Thioctic Acid is available for systemic delivery via both the oral and intravenous (IV) route of administration. The drug is manufactured in several general dosage form(s), commonly including oral solid forms such as tablets or capsules, and sterile parenteral solutions suitable for infusion. The high-level composition confirms that Thioctic Acid is the sole active pharmaceutical ingredient. Structurally, Alpha-lipoic acid is unique because it is an amphipathic molecule, meaning it is soluble in both water and fat, allowing it to function as a powerful free radical scavenger across all cellular compartments. This means Alpha-lipoic acid can protect the body's cells in diverse environments.


The General Purpose of This Metabolic Agent

The general purpose of Thioctic Acid is to support cellular function and health by optimizing energy pathways and providing wide-ranging protection against damage from oxidative stress. By acting as a critical coenzyme necessary for major mitochondrial enzyme complexes and by neutralizing harmful free radicals, this metabolic agent helps stabilize and maintain the functional integrity of tissues throughout the body. A typical, neutral scenario involves the use of this medicine for its general metabolic support in conditions characterized by elevated oxidative stress and compromised energy supply. The benefit centers on supporting the metabolic health of cells, which is particularly crucial for tissues highly susceptible to metabolic stress, such as peripheral nerves.

Regulatory References

  1. National Institutes of Health (NIH) confirms
Advertisements

What side effects are possible with Ala (Thioctic Acid)?

Possible Side Effects and Safety Information

The safety profile of Thioctic Acid (Alpha-lipoic acid, ALA) is established through official governmental regulatory documents, which categorize adverse reactions by frequency and affected organ system. This information strictly outlines documented risks without providing clinical advice or dosing instructions.


Documented Adverse Reactions

The most commonly noted adverse reactions are often linked to the immune system or metabolism, affecting the skin or blood sugar levels.

Category Documented Adverse Reactions
Frequency Unknown Insulin Autoimmune Syndrome (IAS), Allergic skin reactions (urticaria, itching, skin rash), Systemic allergic reactions, Hypoglycaemia-like symptoms (dizziness, sweating, headaches).
Very Rare Changes and/or disturbances to the sense of taste, Convulsion, Double vision, Purpura.

Serious adverse events are explicitly documented in regulatory labeling. These include Systemic allergic reactions, including anaphylactic shock, and Insulin Autoimmune Syndrome (IAS). The label also notes that very high-dose overdose may result in severe systemic harm such as seizures and lactic acidosis, especially when combined with alcohol.


Safety Considerations for Specific Populations

Official prescribing information addresses safety for specific groups and situations:

  • Genetic Risk: Individuals with certain Human Leukocyte Antigen (HLA) genotypes are documented as having an increased susceptibility to developing IAS.
  • Pregnancy and Lactation: Due to inconclusive or inadequate human safety data, use during these periods requires a careful consideration of the official benefit/risk ratio.
  • Time-Related Pattern: Documented metabolic effects, such as hypoglycaemia-like symptoms, have been observed to resolve upon cessation of the medicine.
Advertisements

Overdose and Emergency Response

Documented Overdose Manifestations

Initial manifestations of Thioctic Acid (ALA) overdose may include non-specific symptoms such as nausea, vomiting, and headache, as listed in regulatory documents. A significant overdose can rapidly escalate into severe or sometimes lethal poisoning characterized by major systemic effects.

Severe and Life-Threatening Outcomes

These serious manifestations documented in official labeling include seizures with loss of consciousness, profound metabolic acidosis due to increased lactic acid, serious disturbances of blood clotting (coagulopathy), a drop in blood sugar (hypoglycemia), and systemic collapse leading to shock. Furthermore, severe toxicity can involve rhabdomyolysis (muscle damage), hemolysis (red blood cell destruction), and subsequent multiple organ dysfunction.

Population Risk and Required Emergency Action

The most severe poisonings, including lethal cases, are often associated with the co-ingestion of high doses (over 10 g) of Thioctic Acid and alcohol. Due to the high risk of life-threatening complications, regulatory guidance strictly mandates that individuals who suspect a significant overdose must seek prompt transportation to the hospital. The official instructions for management specify following general treatment principles for cases of poisoning, as no specific antidote is known. Hospital observation is required to manage the documented severe systemic risks.

Advertisements

Therapeutic Uses of Ala (Thioctic Acid)

What Alpha-Lipoic Acid (Thioctic Acid) treats: main uses and benefits

Alpha-lipoic acid (ALA), also known as thioctic acid, is primarily utilized to help alleviate symptoms associated with diabetic polyneuropathy, a type of nerve damage that is a common complication of diabetes. Its application focuses on managing the needs of individuals experiencing discomfort in their extremities.

Scientific literature suggests it is a well-studied agent for addressing the needs of individuals with diabetic neuropathy. Its potential application is tied to findings suggesting it may improve symptoms such as paresthesia and pain. This application may help address specific symptoms, including pain, burning, and numbness in the arms and legs.

Additionally, while diabetic neuropathy is the main established use, ALA is also a subject of research for its potential role in the management of other chronic conditions linked to oxidative factors, such as metabolic syndrome, and its exploration extends to supporting glucose metabolism. The expected role of ALA involves the potential for symptom alleviation and providing support in chronic condition management.

Quick Fact: Relief for Diabetic Neuropathy Symptoms

Regulatory References

  1. Alpha-Lipoic Acid - StatPearls - NCBI Bookshelf
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Ala (Thioctic Acid)?

Official regulatory documents define the strict eligibility criteria for using Ala (Thioctic Acid), primarily based on age, hypersensitivity, and physiological status. The medicine is primarily indicated for use in the adult population (18 years and older).


Absolute Non-Eligibility

Thioctic Acid is contraindicated and must not be used by any patient with a known hypersensitivity or allergy to the active substance, Thioctic Acid, or to any excipients present in the formulation. This is the main absolute restriction found in official labeling.

Eligibility by Age

The medicine is not recommended for children and adolescents. This restriction is due to a lack of sufficient clinical experience and safety data to establish its use in the pediatric population.

Conditional Use Restrictions

Use is restricted and requires special consideration in several patient groups:

  • Pregnancy and Lactation: Use during these periods is only permitted after a physician performs a stringent determination of the indication due to the absence of adequate human safety data.
  • Hepatic Impairment: Caution is necessary when using the medicine in patients with liver impairment because clinical experience is limited.
  • Genetic Risk: Special attention is noted for patients with specific genetic factors, such as the *HLA-DRB104:06 allele**, who may have an increased risk of Insulin Autoimmune Syndrome (IAS).
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Thioctic Acid (ALA) through specific pharmacodynamic and exposure-altering patterns. The profile requires restrictions in co-administration to manage potential effects on blood sugar, drug absorption, and co-medication efficacy.


Documented Pharmacodynamic Interactions

Co-administration with Insulin and oral antidiabetic agents (such as Sulfonylureas or Glinides) can result in a reinforced blood-sugar lowering effect. This interaction is officially described as an increased risk of hypoglycemia.

The regulatory profile also notes that Thioctic Acid may lead to a decrease in the effectiveness of co-administered thyroid hormones.


Exposure-Altering Interactions and Timing Rules

Products containing Ferric Cations and iron salts interfere with the absorption of Thioctic Acid. This causes a reduction in systemic exposure and may compromise the efficacy of ALA. Due to this interference, a mandatory separation in administration time is required between Thioctic Acid and iron-containing products.

Other Official Interaction Notes

  • Cisplatin: Co-administration with the chemotherapy agent Cisplatin is noted for potentially reducing the cytotoxicity (therapeutic effect) of Cisplatin.
  • Alcohol: Regular intake of alcohol is documented as potentially impairing the success of treatment for neuropathic conditions.
  • Population Note: Regulatory bodies have documented an increased susceptibility to Insulin Autoimmune Syndrome (IAS) in patients with specific HLA genotypes treated with Thioctic Acid, representing a population-specific interaction consideration.
Advertisements

Mechanism of Action

Thioctic acid (alpha-Lipoic acid, ALA) is an amphipathic dithiol compound readily absorbed and transported into intracellular compartments, including the mitochondria and cytosol, and crosses the blood-brain barrier.

Its mechanism centers on the ALA/DHLA redox couple (dihydrolipoic acid being the reduced form), which directly scavenges reactive oxygen species (ROS) and reactive nitrogen species (RNS). Dihydrolipoic acid (DHLA), formed in vivo by enzymes like dihydrolipoamide dehydrogenase and thioredoxin reductase, functions as a potent electron donor. This DHLA activity enables the regeneration of other major endogenous antioxidants, including reduced glutathione (GSH), Vitamin E (alpha-tocopherol), and Vitamin C (ascorbate), sustaining the overall cellular antioxidant capacity. Furthermore, the ALA/DHLA system acts as a chelator of redox-active metal ions like free iron and copper.

At the molecular level, ALA and DHLA modulate key transcription factors. ALA inhibits the degradation of IkappaB (Inhibitor of NF-kappaB), thereby preventing the nuclear translocation and activation of NF-kappaB (Nuclear Factor kappa B), a complex that regulates the transcription of pro-inflammatory genes. Concurrently, it can activate Nrf2 (Nuclear Factor erythroid 2-related factor 2), promoting the transcription of antioxidant response element (ARE)-driven cytoprotective genes, including those for GSH synthesis enzymes. These intracellular consequences result in a system-level modulation characterized by a net shift toward a more reduced cellular redox state and an attenuation of pro-inflammatory signaling pathways.

Advertisements

Dosage and Administration Information

Administration Scope and Dosage

The application of Ala (Thioctic Acid) follows a standardized, two-phase regimen, with a consistent 600 mg daily dose in both phases.

Feature Instruction Summary
Route of administration Intravenous (IV) infusion for the initial intensive treatment phase, followed by oral administration for continuation therapy.
Dosing schedule A consistent daily dose of 600 mg is utilized for both the initial IV phase and the long-term oral maintenance phase.
Timing in relation to meals Oral forms (tablets or capsules) should generally be taken after meals with a sufficient amount of liquid.
Age-group rules The product is not recommended for use in children and adolescents (under 18 years) due to a lack of sufficient clinical experience and data.

Procedural Administration Guidelines

Step sequence:

  • Phase 1: Initial Intensive Treatment involves the daily 600 mg intravenous dose, which is typically administered over a course lasting 2 to 4 weeks.
  • The parenteral solution requires specialized handling, including administration slowly over a period of at least 30 minutes as a short infusion.
  • Due to photosensitivity, the infusion vial must be protected from light and administration must begin immediately after opening the vial.
  • Phase 2: Long-Term Maintenance involves switching to the oral administration of a 600 mg dose, taken once daily.

Special procedural conditions: A forgotten intravenous dose should not be compensated by taking a double dose.

This protocol outlines the precise, standardized delivery method for the medicine.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ala (Thioctic Acid)


Evidence for use in Diabetic Polyneuropathy Symptoms

Research has extensively explored the compound Thioctic Acid (ALA) in the context of symptoms associated with diabetic polyneuropathy (nerve damage) in people with diabetes. These investigations have primarily used Randomized Controlled Trials (RCTs), often comparing the compound to a placebo. These trials were used in research exploring how symptom intensity changes over time in study participants.

Studies focused on outcomes related to physical discomfort, specifically measuring changes in patient-reported scores for symptoms like pain, burning, and numbness. Findings from short-term studies using intravenous (IV) administration reported measured symptomatic scores that were lower in the studied population over a few weeks. The evidence reflects findings only for the specific conditions and short follow-up durations studied.

Data for longer-term use, especially with oral forms, show patterns that were mixed. Research provides context on short-term variations in symptom patterns, but data are limited in showing whether this affects the progression of the underlying nerve damage over a sustained period.


Evidence in Related Metabolic Contexts and Biomarkers

Thioctic Acid was also evaluated in research contexts involving systemic or functional imbalance, focusing on its role as a metabolic agent. These studies examined populations with conditions such as Metabolic Syndrome or who are overweight.

Research explored changes measured during the study period for parameters like fasting blood sugar, markers of insulin function, and blood fats (lipids). Findings describe patterns where some trials reported measured changes in blood lipid levels, specifically triglycerides, in certain populations. Data show patterns related to core measures of blood sugar control that were often reported to be modest or limited compared to placebo.


Key Research Gaps and Remaining Uncertainty

One key limitation is the methodological inconsistency and variation in findings between trials that used intravenous infusions for short-term pattern observation and those that evaluated oral administration over longer periods. Furthermore, comparative evidence is lacking regarding the consistent long-term change in objective measures of nerve function. The long-term effects are not fully established regarding whether the compound is associated with changes in the physical progression of nerve damage.

Key Studies & References

  1. Alpha-Lipoic Acid - StatPearls - NCBI Bookshelf
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Ala (Thioctic Acid) (FAQ)


Q: Can I take Thioctic Acid at the same time as my daily vitamins?

Official product information notes that certain products containing ferric cations or iron salts can interfere with the body's absorption of Thioctic Acid. This interference can compromise the medication's effectiveness. Therefore, official guidance notes that a separation in administration time is indicated between Thioctic Acid and any iron-containing vitamins or supplements.

Q: Is there a difference in effectiveness between the oral tablets and the intravenous (IV) form of Ala?

Official information regarding clinical research notes a methodological inconsistency between the short-term studies that used intravenous infusions and the longer-term studies that evaluated oral administration. Because of this variation, there is a limitation in making a direct comparison about the long-term effectiveness of the two forms.

Q: Is it necessary to have a prescription to get Ala?

The regulatory status of Alpha-Lipoic Acid varies by country and by formulation. In some jurisdictions, the high-dose intravenous solution is typically regulated as a prescription-only medicine. Conversely, some oral products containing lower doses may be available for purchase over-the-counter, depending on local regulations.

Q: What happens if a person accidentally misses a dose of Thioctic Acid?

Official procedural guidelines state that a forgotten intravenous dose should not be compensated by taking a double dose. For any missed oral dose during the maintenance phase, official guidance suggests consulting a healthcare professional for specific guidance on how to proceed.

Q: Can Thioctic Acid be used safely for long periods of time?

The standard administration protocol for this medicine includes an initial phase followed by a long-term oral maintenance phase. While this indicates the medicine is intended for extended use, regulatory evidence notes that long-term data are mixed. Research on the effects of continued use on the physical progression of nerve damage is not yet fully established.

Q: Is it possible for Ala to cause changes in taste or smell?

Official regulatory documents list changes and disturbances to the sense of taste as a documented, very rare adverse reaction. However, the official prescribing information does not include any mention of a change or disturbance to the sense of smell.

Q: What happens to Ala in the body after it is taken?

Thioctic Acid is readily absorbed from the site of administration. Once in the bloodstream, the substance is quickly transported into various internal cell parts, known as intracellular compartments, including the mitochondria and cytosol. It is also documented that the medicine crosses the blood-brain barrier to reach the central nervous system.

Q: What are the general expectations for patients starting treatment with Ala?

General expectations are guided by clinical research findings reported in regulatory documents. These studies reported that patient-reported scores for symptoms like pain, burning, and numbness were lower in the studied populations following the initial, short-term intravenous phase of treatment.

Q: Can taking Thioctic Acid cause stomach or digestive issues?

Yes, official patient information summaries often list gastrointestinal issues among the common side effects. These digestive concerns may include nausea and vomiting.

Q: Does Ala interact with common over-the-counter pain relievers?

Currently, official drug interaction summaries and checkers generally report no known interaction between Alpha-Lipoic Acid and the common over-the-counter pain reliever acetaminophen.

Q: How long does it typically take to start noticing any effects from Ala?

Research supporting the medicine's use reported measured symptomatic scores over a period of a few weeks. This corresponds with the typical duration of the initial intensive intravenous treatment phase, which usually lasts between two and four weeks.

Q: How long can I store this medication before it expires?

Provided the medication is stored correctly in its original container, protected from light, heat, and moisture, the typical shelf life is 3 years. The product should not be used after the expiry date that is printed on the packaging.

Q: What is the difference between pharmaceutical grade Ala and dietary supplements containing Alpha-Lipoic Acid?

Pharmaceutical Thioctic Acid is often manufactured as a racemic mixture, meaning it contains both the R-(+) and S-(-) forms of the molecule. The R-(+) enantiomer is the naturally occurring form, and some supplements may specify that they contain only this version.

Q: Is it necessary to monitor certain body functions while taking Ala?

Official information indicates that close patient monitoring is often indicated. This is due to the potential for a blood-sugar-lowering effect (hypoglycemia) and the specific risk of Insulin Autoimmune Syndrome (IAS) in genetically predisposed patients.

Q: Are there different forms of the drug, such as R-Lipoic Acid?

Yes, Alpha-lipoic acid exists in different forms. The standard pharmaceutical ingredient is typically a racemic mixture containing both the R-(+) form, which is understood to be the naturally occurring and biologically active version, and the S-(-) form, which is synthetic.

Q: Are there any warnings about driving or operating machinery while taking Thioctic Acid?

Official documentation lists adverse reactions such as dizziness or blurred vision. Patients who experience these effects are advised to use caution when performing tasks that require concentration, such as driving or operating machinery.

Q: Is Ala known to cause weight changes?

Weight changes are not listed as an official side effect in regulatory adverse reaction documents. However, clinical research has investigated the substance's impact in metabolic contexts and has sometimes reported a small, minor reduction in body weight in specific study populations.

Q: Is there any research on Ala and eye health?

Research has examined the use of Alpha-lipoic acid for diabetic retinopathy, which is vision trouble related to diabetes. However, the available scientific evidence generally suggests that the compound may have little or no measurable effect on eye damage.

Advertisements

How should Ala (Thioctic Acid) be stored and disposed of?

How to Store and Dispose of Ala (Thioctic Acid)

Storage and disposal of Thioctic Acid must adhere to regulatory labeling requirements to maintain product stability and ensure public safety.


Official Storage Conditions

Thioctic Acid is generally required to be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). The product must be stored in its original container and must be actively protected from heat, light, and moisture. It is prohibited to freeze the medicine. Since Thioctic Acid is a medicinal product, it must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Thioctic Acid must be disposed of in accordance with local and national pharmaceutical waste regulations. The medicine must not be emptied into drains or household wastewater systems. Disposal typically requires using an approved waste disposal method.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ala (Thioctic Acid) found in:

A-Z Index: